Interprétation IA fondée sur des extraits vérifiés. Les déclarations de l’entreprise et les limites de couverture restent explicites.
Méthode quality-scores-2 : six catégories de même poids. Le score global exige une couverture complète. Les données manquantes ne valent pas zéro. Les évaluations qualitatives sont des interprétations sourcées, pas des probabilités. 4/6 · 22/10/2026
Moat63
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 3/4 · Extensive accumulated clinical evidence, commercially approved therapies, patent rights and costly approval requirements support a demonstrated intangible-assets barrier. This conclusion rests on specific achievements and adoption, rather than margins or unsupported leadership descriptions.
durability · 3/4 · Long commercialization history, multiyear clinical follow-up and continued sales growth demonstrate persistence. These support strong historical durability, while missing patent-life and competitor-outcome evidence prevent an exceptional grade.
customer dependency · 2/4 · Large cumulative use and growing sales indicate sustained clinical demand indirectly. They do not establish hospital lock-in, exclusive purchasing or costly switching between competing devices.
erosion resilience · 2/4 · Growing sales and stable recent TAVR prices indicate resilience. Mutual patent access, royalties, actual litigation costs and procedure constraints temper that evidence; part of recent growth benefited from a competitor exit.
Pouvoir de fixation des prix56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 2/4 · Global TAVR average selling prices were stable in both reported 2026 quarters. This is an observed resilient pricing outcome, but the short history and absence of other product-group pricing limit the conclusion.
retention · 3/4 · Repeated annual sales growth across all three product groups and SAPIEN's extensive cumulative clinical use support sustained demand. This is indirect operating evidence of continued adoption, not a measured customer retention rate or proof of switching costs.
margin resilience · 2/4 · Second-quarter gross margin remained broadly stable as manufacturing savings offset currency pressure, following first-quarter compression. First-half operating income increased, but 2025 litigation expenses demonstrate material economic costs. Margins do not independently prove pricing power.
contractual freedom · 2/4 · Negotiated end-customer prices and volume rebate arrangements show some ability to negotiate terms, coupled with meaningful buyer bargaining and reimbursement-related price sensitivity. Unilateral repricing rights and contract duration protections are not established.
Prévisibilité84
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 75.00
- Revenue growth volatility (pp)
- 8.59
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 7.73
Solidité financière—
Missing required inputs: debtFcfGrade, netDebtEbitGrade. Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- interestCoverageGrade
- 100.00
- currentRatioGrade
- 100.00
- Interest coverage (x)
- 61.97
- Current ratio (x)
- 3.72
Allocation du capital—
Missing required inputs: operatingReturn. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year average dilution (%)
- -1.88
- 3-year average SBC / revenue (%)
- 2.64
- cashConversionGrade
- 34.10
Qualité du management69
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Operating cash generation, documented investment outlays, repurchases and lower weighted-average shares demonstrate active capital management. Repeated investment impairments in 2025 and 2026 make allocation outcomes mixed. Cash-flow growth partly reflected lower tax payments; buybacks alone do not prove value creation.
incentive alignment · 3/4 · All NEOs reportedly met ownership targets, actual 2025 performance awards used multiyear relative TSR, and the 2022 PBRSUs were forfeited entirely after underperformance. Those are demonstrated alignment mechanisms. Removing free cash flow from annual incentives weakens direct cash-discipline incentives.
execution · 3/4 · Commercialization of multiple therapies, multiyear product sales growth and increased first-half 2026 operating income demonstrate execution through operating outcomes. These indirectly assess management effectiveness; investment failures and hospital capacity constraints remain meaningful limitations.
governance · 3/4 · An independent chair, a board independent except for the CEO, annual elections, stockholder rights and an implemented reduction in the special-meeting threshold provide concrete governance evidence. Actual incentive forfeiture supports enforcement. The historical voluntarily disclosed FCPA investigation remains an unresolved limitation in these passages, rather than proof of misconduct.
Preuves
SAPIEN is the most studied valve in the world, with more than 15 years of distinguished clinical trials involving over 10,000 patients, 10 New England Journal of Medicine publications and 1.2 million patients treated around the world.
Business / TAVR clinical history and treated population · Dépôt 25/02/2026
Edwards' transcatheter aortic heart valves were first commercialized in Europe in 2007, in the United States in 2011, and in Japan in 2013.
Business / TAVR commercialization history · Dépôt 25/02/2026
In 2024, EARLY TAVR trial data demonstrated the superiority of early TAVR intervention in severe asymptomatic aortic stenosis patients with the SAPIEN 3 platform versus clinical surveillance.2 The SAPIEN 3 platform was the world’s first transcatheter heart valve with a transcatheter heart valve in the transcatheter heart valve (“THV-in-THV”) indication for patients assessed at high-risk for surgical replacement, offering patients the ability to have a second minimally invasive procedure.
Business / EARLY TAVR results and indication · Dépôt 25/02/2026
The PASCAL transcatheter repair system (in Europe, the United States, and Japan), EVOQUE tricuspid valve replacement system (in Europe and the United States), and SAPIEN M3 mitral valve replacement system (in Europe and the United States) are commercially available.
Business / commercially available TMTT therapies · Dépôt 25/02/2026
Our differentiated RESILIA tissue technology, with published clinical data showing over 99% freedom from structural valve deterioration through eight years,3 has set the new standard for tissue valve durability.
Business / RESILIA eight-year clinical outcome · Dépôt 25/02/2026
We own or have rights to a substantial number of patents and have patent applications pending both in the United States and in foreign countries.
Business / patent rights · Dépôt 25/02/2026
As of or for the Years Ended December 31, 2025 2024 2023 (in millions) Net Sales by Major Product Group Transcatheter Aortic Valve Replacement $ 4,487.7 $ 4,106.1 $ 3,879.8 Transcatheter Mitral and Tricuspid Therapies 550.6 352.1 197.6 Surgical Structural Heart 1,029.3 981.3 932.6 $ 6,067.6 $ 5,439.5 $ 5,010.0 Long-lived Tangible Assets by Geographic Region United States $ 1,259.7 $ 1,249.6 $ 1,186.9 Other countries 654.9 534.6 488.5 $ 1,914.6 $ 1,784.2 $ 1,675.4 105 Table of Contents EDWARDS LIFESCIENCES CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 22.
Note 21 / 2023–2025 sales by product group · Dépôt 25/02/2026
The process of obtaining FDA clearance or approval to market a product is resource intensive, lengthy, and costly.
Government regulation / FDA approval burden · Dépôt 12/02/2024
In TAVR, our primary competitors include Medtronic plc (“Medtronic”) and Abbott Laboratories (“Abbott”).
Competition / named TAVR competitors · Dépôt 25/02/2026
In Surgical, our primary competitors include Medtronic and Abbott.
Competition / named Surgical competitors · Dépôt 25/02/2026
On April 12, 2023, we entered into an intellectual property agreement with Medtronic pursuant to which the parties agreed to a 15-year global covenant not to sue ("CNS") for infringement of certain patents in the structural heart space owned or controlled by each other.
Liquidity and capital resources / 15-year mutual patent covenant · Dépôt 28/02/2025
In consideration for the global CNS and related mutual access to certain intellectual property rights, we paid Medtronic a one-time, lump sum payment of $300.0 million and are making annual royalty payments that are tied to net sales of certain Edwards products.
Liquidity and capital resources / patent-access payment and royalties · Dépôt 28/02/2025
We have in the past and are continuing to experience constrained procedure volumes and sales for our products because more products, including Edwards’ own products, are competing for the same facilities and staffing within hospitals.
Risk factors / realized procedure and sales capacity constraints · Dépôt 25/02/2026
Our present or future products could be rendered obsolete or uneconomical as a result of technological advances by one or more of our present or future competitors or by other therapies, including drug therapies.
Competition / potential technological obsolescence · Dépôt 25/02/2026
The items described below are adjustments to the GAAP financial results in the reconciliations that follow: Certain Litigation Expenses, net - Our Company incurred certain litigation expenses of $325.4 million and $40.4 million in 2025 and 2024, respectively.
Non-GAAP reconciliation / 2025 and 2024 litigation expenses · Dépôt 26/03/2026
and outside of the U.S. Growth benefitted from the exit of a competitor in Q2 2025 and compelling long-term SAPIEN durability data.
Second-quarter 2026 TAVR discussion / competitor-exit contribution · Dépôt 23/07/2026
These various initiatives have created increased price sensitivity over medical products generally and may impact demand for our products and technologies.
Health care initiatives / increased market price sensitivity · Dépôt 25/02/2026
Average selling prices were stable globally.
First-quarter 2026 TAVR discussion / realized global selling prices · Dépôt 23/04/2026
Average selling prices were stable globally.
Second-quarter 2026 TAVR discussion / realized global selling prices · Dépôt 23/07/2026
The Company's sales adjustment related to distributor rebates given to the Company's distributors represents the difference between the Company's sales price to the distributor and the negotiated price to be paid by the end-customer.
Revenue recognition / negotiated end-customer prices · Dépôt 25/02/2026
The Company offers volume rebates to certain group purchasing organizations (“GPOs”) and customers based upon targeted sales levels.
Revenue recognition / volume rebate terms · Dépôt 25/02/2026
For the quarter, gross profit margin was 77.5%, or 77.6% adjusted, consistent with the same period last year and driven by foreign exchange headwinds offset by lower manufacturing expenses.
Additional financial results / second-quarter gross margin and cost offsets · Dépôt 23/07/2026
For the quarter, gross profit margin was 78.0%, or 78.2% adjusted, compared to 78.7% in the same period last year.
Additional financial results / first-quarter gross margin comparison · Dépôt 23/04/2026
The year-over-year change was driven by a weakening dollar as well as additional manufacturing expenses related to the expansion of new therapies.
Additional financial results / currency and manufacturing cost explanation · Dépôt 23/04/2026
1 Table of Contents EDWARDS LIFESCIENCES CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share information; unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net sales $ 1,741.0 $ 1,532.2 $ 3,389.6 $ 2,944.9 Cost of sales 392.4 344.4 755.0 646.0 Gross profit 1,348.6 1,187.8 2,634.6 2,298.9 Selling, general, and administrative expenses 561.2 502.0 1,083.4 967.7 Research and development expenses 278.9 276.2 542.2 530.8 Certain litigation expenses 6.3 15.5 43.4 26.4 Separation costs — 4.2 — 8.4 Other operating income (11.0) (21.3) (25.2) (40.4) Operating income, net 513.2 411.2 990.8 806.0 Interest income, net (30.0) (37.4) (63.5) (73.9) Loss on impairment (Note 6) 40.0 47.1 163.6 47.1 Other non-operating (income) expense, net (Note 7) (16.6) 1.3 (88.1) (1.3) Income from continuing operations before provision for income taxes 519.8 400.2 978.8 834.1 Provision for income taxes 278.4 64.3 356.7 134.6 Net income from continuing operations 241.4 335.9 622.1 699.5 Loss from discontinued operations, net of tax — (4.4) — (11.6) Net income 241.4 331.5 622.1 687.9 Less: Net loss attributable to noncontrolling interest (0.5) (1.7) (0.5) (3.3) Net income attributable to Edwards Lifesciences Corporation $ 241.9 $ 333.2 $ 622.6 $ 691.2 Share information (Note 14) Earnings (loss) per share: Basic Continuing operations $ 0.42 $ 0.58 $ 1.08 $ 1.20 Discontinued operations $ — $ (0.01) $ — $ (0.02) Basic earnings per share $ 0.42 $ 0.57 $ 1.08 $ 1.18 Diluted Continuing operations $ 0.42 $ 0.57 $ 1.07 $ 1.20 Discontinued operations $ — $ (0.01) $ — $ (0.02) Diluted earnings per share $ 0.42 $ 0.56 $ 1.07 $ 1.18 Weighted-average number of common shares outstanding: Basic 576.4 587.0 577.8 586.9 Diluted 577.6 587.9 579.2 587.9 The accompanying notes are an integral part of these condensed consolidated financial statements.
Statements of operations / first-half 2026 operating results and share counts · Dépôt 04/08/2026
Net cash flows provided by operating activities of $695.7 million for the six months ended June 30, 2026, increased $125.1 million over the same period last year primarily due to lower tax payments during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, which primarily included $160.0 million of local tax payments associated with the sale of Critical Care and higher tax payments related to the U.S.
Consolidated cash flows / operating cash generation and tax-payment contribution · Dépôt 04/08/2026
Net cash used in investing activities of $286.0 million for the six months ended June 30, 2026, consisted primarily of capital expenditures of $131.8 million, issuance of notes receivable of $53.2 million, and net payments of $33.7 million related to business combinations, partially offset by net purchases of investments of $63.0 million.
Consolidated cash flows / capital expenditure and investment outlays · Dépôt 04/08/2026
During the six months ended June 30, 2026, under the Board-authorized repurchase program, we repurchased a total of 6.9 million shares at an aggregate cost of $558.7 million, including pursuant to a $500.0 million accelerated share repurchase agreements executed during the period (see Note 11 to the Condensed Consolidated Financial Statements).
Liquidity and capital resources / completed first-half share repurchases · Dépôt 04/08/2026
Loss on Impairment Loss on impairment of $40.0 million and $163.6 million in the three and six months ended June 30, 2026, respectively, were due to the termination of the option agreement to acquire one of our VIE investments and the carrying amount of another VIE investment not being recoverable (see Note 6 to the Condensed Consolidated Financial Statements).
Loss on impairment / realized first-half 2026 investment losses · Dépôt 04/08/2026
Loss on Impairment - Our Company recorded loss on impairment of $146.9 million ($112.5 million net of tax) in 2025 related to the Company's determination to not exercise an option to acquire one of its VIE investments and impairment of its investment in JenaValve Technologies.
Non-GAAP reconciliation / realized 2025 investment impairments · Dépôt 26/03/2026
(See “Executive Compensation and Other Information—Compensation Discussion and Analysis—Stock Ownership Guidelines and Holding Requirement.”) All NEOs have met their ownership targets; •The Long-Term Stock Program is a component of total executive direct compensation (base salary plus target annual cash incentive plus grant date fair value of equity awards), which is generally positioned to approximate the median for comparable positions at competitive peer companies (See “Executive Compensation and Other Information—Compensation Discussion and Analysis—Compensation Process.”); •The maximum term of options is seven years; •Awards generally have a minimum vesting period of three years; •In 2025, we awarded PBRSUs to the NEOs that require achievement of performance goals based on relative TSR over a three-year performance period; •We do not have any program, plan or practice to time option grants in coordination with the release of material information.
Long-Term Stock Program discussion / ownership compliance and actual 2025 awards · Dépôt 26/03/2026
Our Compensation and Governance Committee determined that as of April 30, 2025, our relative TSR was -7.95% points below the median and, in line with our pay-for-performance philosophy, the 2022 PBRSUs were forfeited in their entirety with no payout.
2022 PBRSU determination / actual forfeiture without payout · Dépôt 26/03/2026
Note that in order to align our business, strategy and incentive programs, our Compensation and Governance Committee had decided to remove free cash flow from the Annual Cash Incentive Program for the 2025 year and going forward.
Annual Cash Incentive Program / removal of free cash flow measure · Dépôt 26/03/2026
☑ WHAT WE DO P Independent Board, all but our Chief Executive Officer ("CEO") P Independent Board leadership, with an independent Board Chair since 2024 P All directors are elected annually for one-year terms P Director education program aligned with corporate strategy P Majority vote standard in uncontested elections, with director resignation policy P Commitment to broad Board capabilities and experience P Executive session of independent directors held at each regularly scheduled Board and committee meeting P Ongoing Board refreshment and retirement age policy for directors to facilitate periodic board refreshment P Annual Board and committee self-evaluations and peer reviews P Stock ownership guidelines for nonemployee directors, who are expected to own Edwards stock equal to $550,000 and hold 50% of net shares received upon vesting or exercise of equity awards until Board service ends P Senior management succession planning regularly considered at scheduled Board meetings P Proactive stockholder outreach and engagement P Robust code of ethics in our Global Business Practice Standards P Active Board oversight of enterprise risks and risk management P Robust corporate impact* disclosure P Special stockholders’ meetings can be called by stockholders owning at least 15% of our outstanding shares, which is a lower threshold than the threshold adopted by the majority of S&P 500 companies P Proxy access right to permit a stockholder, or a group of up to 30 stockholders, owning at least 3% of our outstanding shares continuously for at least 3 years, to nominate up to the greater of 2 directors or 20% of our Board for inclusion in our annual meeting proxy statement P Clawback policy for incentive-based compensation * Our sustainability program was rebranded as our "corporate impact" program in 2023.
Corporate governance practices / board independence and stockholder rights · Dépôt 26/03/2026
• In response to a non-binding stockholder proposal requesting the right to act by written consent, engaged with stockholders representing over 50% of shares then-outstanding to better understand investor views and, in response to feedback received, reduced the minimum ownership threshold to call a special meeting from 25% to 15%
Stockholder engagement / implemented special-meeting threshold reduction · Dépôt 26/03/2026
19. LEGAL PROCEEDINGS
In 2021, the Company initiated an internal review and investigation into whether business activities in Japan and other markets violated certain provisions of the Foreign Corrupt Practices Act ("FCPA").
Legal proceedings / historical internal FCPA investigation · Dépôt 12/02/2024
The Company voluntarily notified the SEC and the United States Department of Justice ("DOJ") during 2021 that it has engaged outside counsel to conduct this review and investigation.
Legal proceedings / voluntary notification to authorities · Dépôt 12/02/2024
In TMTT, our primary competitor is Abbott, and there are a considerable number of large and small companies with development efforts in these fields.
Competition / TMTT competitor and development-stage entrants · Dépôt 25/02/2026
